Literature DB >> 7906678

Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma.

J H Moore1, E J Lesser, D H Erdody, R B Natale, M B Orringer, D G Beer.   

Abstract

The development of esophageal adenocarcinoma is frequently associated with intestinal-type Barrett's metaplasia. Barrett's metaplasia and esophageal adenocarcinomas were examined for expression of the intestinal brush-border-associated hydrolase aminopeptidase N (APN). APN mRNA was detected by utilizing the reverse transcription polymerase chain reaction (RT-PCR) in 50% of Barrett's metaplasia specimens and in 26% of esophageal adenocarcinomas. APN protein was detected by utilizing immunohistochemistry in 84% of Barrett's metaplasia specimens and in 71% of adenocarcinomas, although a decrease or loss of APN protein was sometimes observed in dysplastic Barrett's metaplasia and adenocarcinomas. Alterations in the p53 tumor-suppressor gene have previously been found in both dysplastic Barrett's mucosa and esophageal adenocarcinomas. The same specimens analyzed for APN were examined for the nuclear accumulation of the p53 protein. Utilizing immunohistochemistry, p53 staining was detected in 42% of Barrett's metaplasia specimens, most of which were dysplastic, and in 58% of adenocarcinomas. In the samples positive for p53 protein, gene mutations in exons 5, 7 and 8 were detected by utilizing single-strand conformation polymorphism analysis (SSCP) in 1 Barrett's metaplasia specimen and 6 adenocarcinomas. In Barrett's metaplasia, there was an inverse correlation between APN protein expression and p53 protein accumulation (p < 0.05) suggesting a link between genetic alterations and loss of this marker. The analysis of markers of intestinal differentiation with markers of disease progression may prove to be a useful approach for studying carcinogenesis in Barrett's metaplasia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7906678     DOI: 10.1002/ijc.2910560406

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Cytochromes P450 are expressed in proliferating cells in Barrett's metaplasia.

Authors:  S J Hughes; M A Morse; C M Weghorst; H Kim; P B Watkins; F P Guengerich; M B Orringer; D G Beer
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.

Authors:  L Murray; A Sedo; M Scott; D McManus; J M Sloan; L J Hardie; D Forman; C P Wild
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

3.  Altered expression of TFF-1 and CES-2 in Barrett's Esophagus and associated adenocarcinomas.

Authors:  Charles A Fox; Lisa M Sapinoso; Hong Zhang; Wanghai Zhang; Howard L McLeod; Gina R Petroni; Tarun Mullick; Christopher A Moskaluk; Henry F Frierson; Garret M Hampton; Steven M Powell
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

Review 4.  Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Brian J Reid; Thomas G Paulson; Xiaohong Li
Journal:  Gastroenterology       Date:  2015-07-21       Impact factor: 22.682

5.  Impact of tumor progression on cancer incidence curves.

Authors:  E Georg Luebeck; Kit Curtius; Jihyoun Jeon; William D Hazelton
Journal:  Cancer Res       Date:  2012-10-10       Impact factor: 12.701

Review 6.  Role of p53 assessment in management of Barrett's esophagus.

Authors:  A K Kubba; N A Poole; A Watson
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

7.  Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

Authors:  B J Reid; L J Prevo; P C Galipeau; C A Sanchez; G Longton; D S Levine; P L Blount; P S Rabinovitch
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

8.  Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia.

Authors:  A P Ireland; D K Shibata; P Chandrasoma; R V Lord; J H Peters; T R DeMeester
Journal:  Ann Surg       Date:  2000-02       Impact factor: 12.969

Review 9.  Barrett's esophagus. The significance of p53 in clinical practice.

Authors:  A P Ireland; G W Clark; T R DeMeester
Journal:  Ann Surg       Date:  1997-01       Impact factor: 12.969

10.  The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea.

Authors:  Nayoung Kim; Sung-Il Cho; Hye Seung Lee; Ji Hyun Park; Jee Hyun Kim; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  Dig Dis Sci       Date:  2009-01-29       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.